Recent Updates
Recently added Catalysts
NKTR Positive Sentiment Score: 75/100

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it...

Monday, June 23, 2025 1 min read
Key Takeaway: Nektar Therapeutics has announced that it will host an investor call to review top-line data from the 16-week induction period of its Phase 2b REZOLVE-AD clinical trial. This trial examines rezpegaldesleukin, a T-cell proliferator, for treating moderate-to-severe atopic dermatitis. The event is scheduled for June 24, 2025, and details will be available through a morning press release and on the company's website. A replay of the presentation will also be accessible for at least 30 days post-event.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nektar is set to announce top-line data from a significant clinical trial.
  • The study focuses on a novel treatment for moderate-to-severe atopic dermatitis.
  • The upcoming investor call demonstrates Nektar's commitment to transparency with stakeholders.

Full Press Release Details

SAN FRANCISCO , June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, June 24, 2025 at 8:15am ET / 5:15am PT .
The data will be provided in a morning press release and presented during the webcast. Details on how to access the live webcast of the call will be available in the morning press release and on the Nektar website at www.nektar.com . A replay of the webcast will be available for at least 30 days following the event.
About Nektar Therapeutics
Corey Davis , PhD LifeSci Advisors 212-915-2577 [email protected]
Madelin Hawtin LifeSci Communications 603-714-2638 [email protected]
SOURCE Nektar Therapeutics

21 %

Frequently Asked Questions

When is the Nektar Therapeutics investor call?

The investor call is on Tuesday, June 24, 2025, at 8:15 AM ET.

What is the purpose of the investor call?

The call will review top-line data from the Phase 2b REZOLVE-AD trial.

How can I access the webcast?

Access details will be in a morning press release and on the Nektar website.

What does rezpegaldesleukin target?

Rezpegaldesleukin is a Treg proliferator for atopic dermatitis.

How long will the webcast replay be available?

The webcast replay will be accessible for at least 30 days post-event.

Tags: NKTR Viatris Investor Conferences Healthcare Nektar Therapeutics Rezpegaldesleukin atopic dermatitis clinical trial immunology
Last updated: Jun 23, 2025